The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Could luspatercept modify disease in lower-risk myelodysplastic syndromes?
Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, explores whether effective anemia treatment with luspatercept may extend beyond symptom control in lower-risk myelodysplastic syndromes (MDS), discussing emerging evidence for disease modification, improved cardiovascular biomarkers, and the potential impact of earlier intervention. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
